Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | UTS2R | Q9UKP6 | 5/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
| ▸ | NPY2R | P49146 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4807849 | 1.00 | SLC6A4 (0.41) | SLC6A4HTR6UTS2RKMORORC | |
| SCHEMBL4806408 | 1.00 | SLC6A4 (0.41) | SLC6A4HTR6UTS2RKMORORC | |
| SCHEMBL265784 | 0.92 | SLC6A4 (0.43) | SLC6A4HTR6KMORORC | |
| SCHEMBL4809034 | 0.91 | SLC6A4 (0.40) | SLC6A4HTR6UTS2RKMOSLC6A3 | |
| SCHEMBL4809017 | 0.91 | SLC6A4 (0.40) | SLC6A4HTR6UTS2RKMOSLC6A3 | |
| SCHEMBL4809021 | 0.91 | SLC6A4 (0.40) | SLC6A4HTR6UTS2RKMOSLC6A3 | |
| SCHEMBL22816372 | 0.85 | CSNK2A1 (0.47) | SLC6A4HTR6NPY1RNPY2R | |
| SCHEMBL4800981 | 0.84 | KMO (0.44) | SLC6A4HTR6KMORORC | |
| SCHEMBL4800976 | 0.84 | KMO (0.44) | SLC6A4HTR6KMORORC | |
| SCHEMBL4804316 | 0.84 | KMO (0.44) | SLC6A4HTR6KMORORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417032-B2 | D-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-26 | — | — | US | disclosed |
| EP-1773800-A1 | D-GLUCOPYRANOSYL PHENYL-SUBSTITUTED CYCLENE, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHOD FOR THE PRODUCTION THEREOF | Boehringer Ingelheim International GmbH (DE) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006010557-A1 | D-GLUCOPYRANOSYL PHENYL-SUBSTITUTED CYCLENE, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-02 | — | — | WO | disclosed |
| US-20060025349-A1 | D-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025349-A1 | D-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture | SLC5A1, SLC5A2, SLC2A1 | SLC6A4 143/4885HTR6 2169/4885UTS2R 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.